Cardiology Department, Maria Vittoria Hospital and Department of Public Health and Pediatrics, University of Torino, Torino, Italy.
University Division of Cardiology, Department of Medical Sciences, Città della Salute e Della Scienza, University of Torino, Torino, Italy.
JAMA. 2015 Oct 13;314(14):1498-506. doi: 10.1001/jama.2015.12763.
Pericarditis is the most common form of pericardial disease and a relatively common cause of chest pain.
To summarize published evidence on the causes, diagnosis, therapy, prevention, and prognosis of pericarditis.
A literature search of BioMedCentral, Google Scholar, MEDLINE, Scopus, and the Cochrane Database of Systematic Reviews was performed for human studies without language restriction from January 1, 1990, to August 31, 2015. After literature review and selection of meta-analyses, randomized clinical trials, and large observational studies, 30 studies (5 meta-analyses, 10 randomized clinical trials, and 16 cohort studies) with 7569 adult patients were selected for inclusion.
The etiology of pericarditis may be infectious (eg, viral and bacterial) or noninfectious (eg, systemic inflammatory diseases, cancer, and post-cardiac injury syndromes). Tuberculosis is a major cause of pericarditis in developing countries but accounts for less than 5% of cases in developed countries, where idiopathic, presumed viral causes are responsible for 80% to 90% of cases. The diagnosis is based on clinical criteria including chest pain, a pericardial rub, electrocardiographic changes, and pericardial effusion. Certain features at presentation (temperature >38°C [>100.4°F], subacute course, large effusion or tamponade, and failure of nonsteroidal anti-inflammatory drug [NSAID] treatment) indicate a poorer prognosis and identify patients requiring hospital admission. The most common treatment for idiopathic and viral pericarditis in North America and Europe is NSAID therapy. Adjunctive colchicine can ameliorate the initial episode and is associated with approximately 50% lower recurrence rates. Corticosteroids are a second-line therapy for those who do not respond, are intolerant, or have contraindications to NSAIDs and colchicine. Recurrences may occur in 30% of patients without preventive therapy.
Pericarditis is the most common form of pericardial disease worldwide and may recur in as many as one-third of patients who present with idiopathic or viral pericarditis. Appropriate triage and treatment with NSAIDs may reduce readmission rates for pericarditis. Treatment with colchicine can reduce recurrence rates.
心包炎是心包疾病中最常见的类型,也是胸痛的一个相对常见的病因。
总结心包炎的病因、诊断、治疗、预防和预后的现有证据。
对生物医学中心、谷歌学术、MEDLINE、Scopus 和 Cochrane 系统评价数据库中的人类研究进行了无语言限制的文献检索,检索时间为 1990 年 1 月 1 日至 2015 年 8 月 31 日。在对文献进行回顾和选择荟萃分析、随机临床试验和大型观察性研究后,选择了 30 项研究(5 项荟萃分析、10 项随机临床试验和 16 项队列研究),共纳入 7569 例成年患者。
心包炎的病因可能是感染性的(例如,病毒和细菌)或非感染性的(例如,全身性炎症性疾病、癌症和心脏损伤后综合征)。结核病是发展中国家心包炎的主要病因,但在发达国家仅占不到 5%,其中 80%至 90%的病例是特发性和疑似病毒引起的。心包炎的诊断基于临床标准,包括胸痛、心包摩擦音、心电图改变和心包积液。某些表现特征(体温>38°C[>100.4°F]、亚急性病程、大量积液或填塞、非甾体抗炎药[NSAID]治疗失败)提示预后较差,并确定需要住院治疗的患者。北美和欧洲特发性和病毒性心包炎的最常见治疗方法是 NSAID 治疗。秋水仙碱辅助治疗可改善首发症状,且复发率降低约 50%。对于那些对 NSAID 和秋水仙碱无反应、不耐受或有禁忌证的患者,皮质类固醇是二线治疗方法。未进行预防治疗的患者中约有 30%会复发。
心包炎是全球最常见的心包疾病类型,约有三分之一的特发性或病毒性心包炎患者会复发。适当的分诊和 NSAID 治疗可能会降低心包炎的再入院率。秋水仙碱治疗可降低复发率。